SUMMARY Systolic time intervals, stroke volume, cardiac output and (dZ/dt)/RZ index were serially estimated in 51 normal healthy volunteers at sea level, for ten days after air induction to 3658 m altitude and on return to sea level. The subjects were divided into three groups and were administered a diuretic, beta methyidigoxin and placebo in a double blind protocol. The group on placebo showed an increase in heart rate, reduction in stroke index and cardiac index during high altitude exposure with normalization on return to sea level. A deterioration in left ventricular function as manifested by THE EFFECT OF HIGH ALTITUDE HYPOXIA on human cardiorespiratory dynamics has been the subject of intense research and a number of communications for the last two decades."' Some of these reports, though restricted to a small sample size due to the hostile terrain, logistic problems and invasive nature of investigations, were of immense value in clarifying the genesis of high altitude illnesses.'+ 2, 5-7, ISimultaneously, clinical studies in a large number of patients generated further interest in these problems.3' 4. 8 Emergence of noninvasive methods as reliable indicators of alterations in cardiovascular function prompted us to use such methodology serially in a large sample size to study responses to high altitude exposure. Using systolic time intervals and electrical impedance plethysmography, we detected alterations in pulmonary extravascular water volume, stroke volume, cardiac output and left ventricular function in normal volunteers inducted to 3658 m.1"-'
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Having established that a definite reduction in left ventricular function, stroke volume and cardiac output occurs on acute exposure to high altitude, we planned and conducted a carefully controlled study in which drugs with a possible prophylactic potential were used and their effects on the parameters of myocardial function studied in detail.
Materials and Methods

Subjects
Fifty-one normal healthy male volunteers between 21 and 35 years of age were chosen as the subjects for the study. They were born and brought up at altitudes less than 1000 m and had never visited higher altitudes. They were similar in dietary habits, physical training and anthropometric measurements. They were divided into three groups of 17 each by table of random numbers and assigned to one of the drug groups by a double blind protocol. Once assigned, they continued to take the same drug throughout the entire study period, at fixed constant time intervals.
prolongation of pre-ejection period, increase in PEP/LVET ratio, reduction in (dZ/dt)/RZ index and left ventricular ejection time was also noted at high altitude. The subjects on digoxin maintained normal stroke/cardiac index and did not show any significant change in the parameters of myocardial function. The diuretic group showed more deterioration in the parameters than the placebo group. No significant side effects were noted. Left ventricular dysfunction and reduction of stroke index at high altitudes may be causally related; digoxin administration may prevent them from occurring.
Drugs
The following drugs were used during the trial: l) betamethyl digoxin, 0.1 mg tablets (Lanitop); 2) aldactide (a combination of 25 mg of spironolactone-A and 25 mg of hydrofluamethiazide); 3) placebo.
The drugs were coded and the codes sealed until after the final analysis of data. All subjects received a fixed dose regime of 1 tablet thrice daily (before breakfast, lunch and dinner). The worker in charge of drug administration did not participate in data collection or analysis.
Study Protocol
The study protocol comprised serial estimation of systolic time intervals, stroke volume and cardiac output. The first study was performed at 198 m above sea level (henceforth called sea level) under basal conditions. The subjects then were administered the drugs for five days and the studies repeated on the fifth day of drug therapy to arrive at a second data base with drugs at sea level. The drugs were then withdrawn and the studies repeated after two days of withdrawal. They were again restarted 48 hours before induction to high altitude. The subjects were transported to 3658 m by a pressurized aircraft in 75 SV =p X (L/Zo)' X VET X (dZ/dt) min. Where L = mean distance between the inner electrodes in centimeters, p = resistivity constant of blood at 37°C calculated from hematocrit,17 Zo = the mean transthoracic electrical impedance in ohms, VET = ventricular ejection time in seconds calculated from a point of dZ/dt wave form intersecting zero calibration line to a clear dip (X point) synchronous to aortic closure, dZ/dt (min) = amplitude of dZ/dt in ohm/sec. 6. Heart rate -from RR interval. 7. Cardiac output = SV X heart rate (stroke index and cardiac index obtained from standard nomograms). 8. RZ interval = the distance between the peak of the R wave of ECG and of dZ/dt. '8 9. (dZ/dt)/RZ index. ' The heart rate increased from 58/min at sea level to 73/min on the tenth day at high altitude. The PEP index increased from a control level of 131 msec at sea level to 146 msec on the fifth and tenth days at high altitude. The values returned to normal on third day of return to sea level. The Abbreviations: HR = heart rate; SI = stroke index; CI = cardiac index; PEP I = pre-ejection period index; LVET I = left ventricular ejection time index; QS2I = electromechanical systole corrected for heart rate; RZI = distance between peak of R wave of ECG and peak of impedance cardiogram corrected for heart rate; dZ/dt = amplitude of impedance cardiogram in ohms/sec divided by RZ interval in seconds.
RZ
LVET index decreased from a control value of 388 msec to 352 msec on the tenth day at high altitude and reverted to normal on the third day of return to sea level. The PEP/LVET ratio gradually increased on exposure to high altitude from a control value of 0.346. The peak of 0.438 was noted on the tenth day at high altitude. Reversion to normal occurred on the third day of return to sea level. Out of the 17 subjects none had PEP/LVET ratio over 0.400 at sea level. On the first day at high altitude, one subject showed a PEP/LVET ratio of over 0.400. On the second, third, fourth, fifth and tenth days at high altitude, 5, 6, 9, 1 1 and 14 subjects showed PEP/LVET ratio above 0.400. In 2, 1, 4, and 2 of these, the ratio was above 0.500 on days 3, 4, 5 and 10, respectively. On the third day of return to sea level, none of the subjects had a value above 0.400.
The RZ interval index showed an increase of 10 msec from the control levels and the (dZ/dt)/RZ index decreased to 10.1 from 13.0. These values reverted to normal on return to sea level.
The stroke index decreased from control level of 60 ml/m2 to 38 ml/m2 on the tenth day at high altitude. The cardiac index came down from 3.5 L/min/m2 at sea level to 2.8 L/min/m2. These values were seen on the fourth, fifth and tenth days at high altitude. Reversion to normal occurred immediately on return to sea level. a methyldigoxin (table 2) The subjects receiving digoxin showed an increase in heart rate by 8 beats/min on the tenth day at high altitude. The PEP index did not change significantly from the control levels of 130 msec. The control LVET index at sea level was 374 msec. This came down to 354 msec on the tenth day at high altitude and the change was statistically not significant. The subjects of group III showed an increase in heart rate from the control values of 62/min to 75/min on the tenth day at high altitude. The PEP index was 134 msec before drugs at sea level and increased to 139 msec after diuretics. Exposure to high altitude resulted in a further increase to 152 msec on the tenth day. The maximal reduction of 25 msec in the LVET index on the tenth day at high altitude was not statistically significant. The PEP/LVET ratio was 0.350 prior to drug intake. This increased to 0.399 after five days of diuretics. On exposure to high altitude a further increase to 0.482 was seen on the fifth day. PEP/LVET ratio over 0.400 was observed in eight subjects after drug administration at sea level. On exposure to high altitude, values above 0.400 were noted in 12, 13, 13, 14 and 15 subjects on days 1, 2, 3, 4, 5 and 10, respectively.
Values above 0.500 were observed in 3, 5, 4, 4, 6 and 3 subjects at high altitude on days 1 to 10, respectively.
The RZ interval increased by 10 msec on first day at sea level, but the change was not statistically significant. The (dZ/dt)/RZ index showed significant reduction on days 3, 4 and 5 at high altitude.
The stroke index was 57 ml prior to drug therapy. Administration of diuretics resulted in a moderate diuresis (mean increase in urine output 987 ± 340 ml) and a reduction in stroke index to 41 ml. Exposure to high altitude resulted in a further decrease to 34 ml (P < 0.01). The cardiac index came down from 3.5 to 2.6 L/min/m2 after diuretic intake. Exposure to high altitude did not result in further significant decrease, the reduction in stroke index being compensated. by the tachycardia.
None of the subjects on digoxin or diuretics developed any significant side effects.
Discussion
Elucidation of the physiological alterations secondary to high altitude exposure has been the subject of extensive research in a number of centers. The role of left ventricular dysfunction at altitude has been a subject of conjecture and controversy. Hultgren et al. felt that left ventricular dysfunction did not occur at altitude.2 37 They were supported by other workers who based their opinion on the demonstration of a normal wedge pressure during acute high altitude pulmonary edema.1 20, 21 Kowalski and Anthony subjected volunteers to short-term hypoxia in a chamber and demonstrated an improvement in left ventricular function which was attributed to increased sympathetic activity.2' On the other hand, a large number of other workers have been strongly propounding the development of left ventricular dysfunction at altitude."
In 1975, we reported the results of a preliminary study in which 20 normal volunteers were serially studied after high altitude induction by air." A reduction in myocardial contractility was demonstrated by alterations in systolic time intervals. This study was further extended to cover 83 more subjects who were serially studied at sea level, on high altitude induction by air and road and on deinduction. In these volunteers also we could clearly demonstrate development of left ventricular dysfunction from the second day of exposure gradually deteriorating until 10 days and returning to normal on deinduction. 16 The alterations in stroke volume and cardiac output on high altitude exposure have been the subject of a similar controversy. Earlier workers have felt that stroke volume was unaltered and cardiac output showed a mild increase. '6 27 Later reports, however, showed a reduction of stroke volume and cardiac output.'3"1 We had demonstrated a clear reduction of stroke volume on high altitude exposure in 50 subjects in whom the parameters were estimated by electrical impedance plethysmography.1"
These observations suggested that left ventricular dysfunction could be the cause for the reduction in stroke volume. The current study was, therefore, carried out to support this hypothesis and to demonstrate the effect of a positive inotropic agent, i.e., digoxin, and a diuretic on left VOL 57, No 6, JUNE 1978 ventricular function at high altitude. The drugs were chosen with a view to their possible use as prophylactic agents in high altitude illnesses. The placebo group was similarly studied to confirm our earlier findings and to obtain comparative data simultaneously. As '9 The alterations of these parameters in the placebo group were similar to our previous reports. A reduction in stroke index, cardiac index, LVET 16 hypertensive subjects (group I) with left ventricular (LV) hypertrophy (ECG and echo criteria) and in 17 hypertensive subjects with ECG signs of LV strain (group II), were compared with those in 14 normal individuals. An augmented pulmonary arteriolar resistance (PAR) in group I and to a larger extent in group II accounted for the pulmonary pressure elevation in both groups. Increase in PAR was unrelated to pulmonary blood flow and volume, pleural pressure, arterial PO2, PCO2 and pH, and could not be explained entirely by the left ventricular end-diastolic pressure changes.
In group I, left (L.MSEJR) and right (R.MSEJR) mean systolic ejection rate, stroke index (SI) and mean velocity of circumferential AVAILABLE INFORMATION on the dynamics of the right side of the heart and lesser circulation in systemic hypertension is scanty and somewhat discordant. Normal values of pulmonary pressure in subjects with systemic hypertension have been recorded in some studies.1' 2 Elevated values were detected in hypertensive patients with fiber shortening (VCF) were enhanced in spite of the heightened pressure load on both sides of the heart. In group II, a large reduction of SI, L.MSEJR, R.MSEJR and VCF, as well as the relationship between ventricular filling pressures and SI, documented a compromised performance of both ventricles.
Findings indicate that: systemic hypertension is associated with elevation of pulmonary arterial pressure and of PAR which is not necessarily a consequence of impairment in LV function; LV hypertrophy is associated with enhanced performance of either ventricle; in coincidence with development of ECG signs of LV strain, the performance of both sides of the heart deteriorates.
A functional interdependence of the two ventricles is suggested.
left ventricular failure and were interpreted as a backward effect of this dysfunction. 
